Efficacy outcomes
time-to-first
SECONDARY
The primary efficacy outcome The subgroup of patients with Efficacy outcomesRegarding the co-primary efficacy outcome, a 7-day course of rivaroxaban at a therapeutic dose of 20 mg daily compared to heparin at a prophylactic dose did not improve the 7-category ordinal scale as a measure for the clinical outcome (relative effect 0.5922 [0.4873, 0.6971], Wilcoxon rank-sum test p = 0.085).In an explorative analysis, therapeutic anticoagulation with rivaroxaban, but not thromboprophylaxis with a heparin led to an improvement on the 7-category ordinal scale by WHO in patients with a very high risk as defined by Co-primary efficacy outcome. Seven-category ordinal scale by WHO at baseline (BL) and 7 days post randomization in the subgroup of COVID-19 patients with a The secondary efficacy composite endpoint occurred in 6 patients (10.9%) in the rivaroxaban-group and in 12 patients (21.4%) in the SOC group (time-to-first occurrence of the components of the secondary outcome: HR 0.5; 95% CI 0.15–1.67; p = 0.264) (Fig. Time to first occurrence of one of the components of the secondary efficacy outcomeResults for subgroup analyses concerning the primary and co-primary endpoint are shown in Figs. Forest plot of the results for the primary endpoint Forest plot of the results for the co-primary endpoint, the seven-category ordinal scale by WHO, at day 7. Shown are the subgroups of high risk patients (